Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference

Rhea-AI Summary

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company, announced that CEO Quang Pham will hold one-on-one meetings at the BIO CEO & Investor Conference in New York from February 6-8, 2023. The company is focused on tecarfarin, a novel cardiorenal therapy designated as orphan drug and Fast Track for preventing systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. Tecarfarin has undergone eleven clinical trials with over 1,000 participants and has been well-tolerated. Interested parties can schedule meetings via the BIO Partnering system or contact Cadrenal directly.

PONTE VEDRA, Fla., Feb. 6, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, is available for one-on-one meetings at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on February 6-8, 2023.

Meetings with conference attendees can be scheduled through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering, or by emailing our corporate contacts using the information provided at the end of this press release.

ABOUT CADRENAL THERAPEUTICS, INC.

Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin has been evaluated in eleven human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.  

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com  

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700,
CVKD@lythampartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-2023-bio-ceo--investor-conference-301738951.html

SOURCE Cadrenal Therapeutics, Inc.

FAQ

What is Cadrenal Therapeutics, Inc. focused on?

Cadrenal Therapeutics, Inc. focuses on developing tecarfarin, a novel cardiorenal therapy.

When is the BIO CEO & Investor Conference taking place?

The BIO CEO & Investor Conference is scheduled for February 6-8, 2023.

What is tecarfarin's significance for patients?

Tecarfarin is significant for preventing systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation.

How many clinical trials has tecarfarin undergone?

Tecarfarin has been evaluated in eleven clinical trials with more than 1,000 participants.

How can I schedule a meeting with Cadrenal Therapeutics at the conference?

Meetings can be scheduled through the BIO One-on-One Partnering system or by contacting Cadrenal directly.